Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations.

Fu JF, Klyuzhin I, McKenzie J, Neilson N, Shahinfard E, Dinelle K, McKeown MJ, Stoessl AJ, Sossi V.

Neuroimage Clin. 2019 May 8;23:101856. doi: 10.1016/j.nicl.2019.101856. [Epub ahead of print]

2.

Occult central pontine myelinolysis post liver transplant: A consequence of pre-transplant hyponatremia.

Zhu J, Al-Alkim F, Hussaini T, Vertinsky A, Byrne D, Erb SR, Stoessl AJ, Yoshida EM.

Ann Hepatol. 2019 Apr 24. pii: S1665-2681(19)30054-7. doi: 10.1016/j.aohep.2019.01.004. [Epub ahead of print]

3.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

4.

Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.

Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, Barclay CL, Boiko C, Johnson GA, Fibiger HC, Harrison R, Lewis O, Pritchard G, Howell M, Irving C, Johnson D, Kinch S, Marshall C, Lawrence AD, Blinder S, Sossi V, Stoessl AJ, Skinner P, Mohr E, Gill SS.

J Parkinsons Dis. 2019;9(2):301-313. doi: 10.3233/JPD-191576.

PMID:
30829619
5.

Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.

Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, Barclay CL, Boiko C, Johnson GA, Fibiger HC, Harrison R, Lewis O, Pritchard G, Howell M, Irving C, Johnson D, Kinch S, Marshall C, Lawrence AD, Blinder S, Sossi V, Stoessl AJ, Skinner P, Mohr E, Gill SS.

Brain. 2019 Mar 1;142(3):512-525. doi: 10.1093/brain/awz023.

6.

PET Molecular Imaging in Familial Parkinson's Disease.

Matarazzo M, Wile D, Mackenzie M, Stoessl AJ.

Int Rev Neurobiol. 2018;142:177-223. doi: 10.1016/bs.irn.2018.09.003. Epub 2018 Oct 12. Review.

PMID:
30409253
7.

A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.

Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; and The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group.

J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471.

8.

Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration.

Klyuzhin IS, Fu JF, Hong A, Sacheli M, Shenkov N, Matarazzo M, Rahmim A, Stoessl AJ, Sossi V.

PLoS One. 2018 Nov 5;13(11):e0206607. doi: 10.1371/journal.pone.0206607. eCollection 2018.

9.

Win-Concurrent Sensory Cues Can Promote Riskier Choice.

Cherkasova MV, Clark L, Barton JJS, Schulzer M, Shafiee M, Kingstone A, Stoessl AJ, Winstanley CA.

J Neurosci. 2018 Nov 28;38(48):10362-10370. doi: 10.1523/JNEUROSCI.1171-18.2018. Epub 2018 Oct 29.

10.

Operationalizing Neuroimaging for Disorders of Consciousness in the Canadian Context.

Kaal KJ, Harrison M, Whitehurst DGT, Townson A, Dance D, Stoessl AJ, Illes J.

Can J Neurol Sci. 2018 Nov;45(6):633-635. doi: 10.1017/cjn.2018.316. Epub 2018 Sep 25. No abstract available.

PMID:
30249312
11.

Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.

Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ.

Mov Disord. 2018 Aug;33(8):1213-1227. doi: 10.1002/mds.27438. Review.

PMID:
30230624
12.

Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.

Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA.

Curr Med Res Opin. 2018 Dec;34(12):2063-2073. doi: 10.1080/03007995.2018.1502165. Epub 2018 Aug 20.

PMID:
30016901
13.

Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET.

Fu JF, Klyuzhin I, Liu S, Shahinfard E, Vafai N, McKenzie J, Neilson N, Mabrouk R, Sacheli MA, Wile D, McKeown MJ, Stoessl AJ, Sossi V.

Neuroimage Clin. 2018 May 21;19:652-660. doi: 10.1016/j.nicl.2018.05.022. eCollection 2018.

14.

PBB3 binding in a patient with corticobasal syndrome.

Perez-Soriano A, Matarazzo M, Vafai N, Shahinfard E, Miao Q, Higuchi M, Sossi V, Stoessl AJ.

Mov Disord. 2018 Aug;33(8):1359-1360. doi: 10.1002/mds.27405. Epub 2018 Jun 22. No abstract available.

PMID:
29932465
15.

Conclusions.

Obeso J, Stoessl AJ.

Mov Disord. 2018 May;33(5):701. doi: 10.1002/mds.27432. No abstract available.

PMID:
29878564
16.

The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Liu SY, Wile DJ, Fu JF, Valerio J, Shahinfard E, McCormick S, Mabrouk R, Vafai N, McKenzie J, Neilson N, Perez-Soriano A, Arena JE, Cherkasova M, Chan P, Zhang J, Zabetian CP, Aasly JO, Wszolek ZK, McKeown MJ, Adam MJ, Ruth TJ, Schulzer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2018 Apr;17(4):309-316. doi: 10.1016/S1474-4422(18)30032-2. Epub 2018 Feb 16.

17.

Dyskinesias and levodopa therapy: why wait?

Matarazzo M, Perez-Soriano A, Stoessl AJ.

J Neural Transm (Vienna). 2018 Aug;125(8):1119-1130. doi: 10.1007/s00702-018-1856-6. Epub 2018 Feb 10. Review.

PMID:
29428995
18.

Challenges and unfulfilled promises in Parkinson's disease.

Stoessl AJ.

Lancet Neurol. 2017 Nov;16(11):866-867. doi: 10.1016/S1474-4422(17)30334-4. No abstract available.

PMID:
29029841
19.

DNAJC12 and dopa-responsive nonprogressive parkinsonism.

Straniero L, Guella I, Cilia R, Parkkinen L, Rimoldi V, Young A, Asselta R, Soldà G, Sossi V, Stoessl AJ, Priori A, Nishioka K, Hattori N, Follett J, Rajput A, Blau N, Pezzoli G, Farrer MJ, Goldwurm S, Rajput AH, Duga S.

Ann Neurol. 2017 Oct;82(4):640-646. doi: 10.1002/ana.25048. Epub 2017 Oct 11.

PMID:
28892570
20.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

21.

Homozygous alpha-synuclein p.A53V in familial Parkinson's disease.

Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, Farrer MJ, Nishioka K, Hattori N.

Neurobiol Aging. 2017 Sep;57:248.e7-248.e12. doi: 10.1016/j.neurobiolaging.2017.05.022. Epub 2017 Jun 27.

PMID:
28666710
22.

PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.

Perez-Soriano A, Arena JE, Dinelle K, Miao Q, McKenzie J, Neilson N, Puschmann A, Schaffer P, Shinotoh H, Smith-Forrester J, Shahinfard E, Vafai N, Wile D, Wszolek Z, Higuchi M, Sossi V, Stoessl AJ.

Mov Disord. 2017 Jul;32(7):1016-1024. doi: 10.1002/mds.27029. Epub 2017 Jun 1.

PMID:
28568506
23.

Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review.

Lai J, Heran MKS, Stoessl AJ, Gooderham PA.

Mov Disord Clin Pract. 2017 Mar 27;4(4):607-611. doi: 10.1002/mdc3.12480. eCollection 2017 Jul-Aug.

24.

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.

Wile DJ, Agarwal PA, Schulzer M, Mak E, Dinelle K, Shahinfard E, Vafai N, Hasegawa K, Zhang J, McKenzie J, Neilson N, Strongosky A, Uitti RJ, Guttman M, Zabetian CP, Ding YS, Adam M, Aasly J, Wszolek ZK, Farrer M, Sossi V, Stoessl AJ.

Lancet Neurol. 2017 May;16(5):351-359. doi: 10.1016/S1474-4422(17)30056-X. Epub 2017 Mar 20.

25.

The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system.

Liu SY, Chan P, Stoessl AJ.

Transl Neurodegener. 2017 Feb 20;6:4. doi: 10.1186/s40035-017-0074-8. eCollection 2017. Review.

26.

Glucose utilization: still in the synapse.

Stoessl AJ.

Nat Neurosci. 2017 Feb 23;20(3):382-384. doi: 10.1038/nn.4513. No abstract available.

PMID:
28230843
27.

Gender differences in Parkinson's disease depression.

Perrin AJ, Nosova E, Co K, Book A, Iu O, Silva V, Thompson C, McKeown MJ, Stoessl AJ, Farrer MJ, Appel-Cresswell S.

Parkinsonism Relat Disord. 2017 Mar;36:93-97. doi: 10.1016/j.parkreldis.2016.12.026. Epub 2016 Dec 29.

PMID:
28089265
28.

Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient.

Kordower JH, Goetz CG, Chu Y, Halliday GM, Nicholson DA, Musial TF, Marmion DJ, Stoessl AJ, Sossi V, Freeman TB, Olanow CW.

Ann Neurol. 2017 Jan;81(1):46-57. doi: 10.1002/ana.24820. Epub 2017 Jan 6.

29.

Tau imaging in progressive supranuclear palsy.

Perez-Soriano A, Stoessl AJ.

Mov Disord. 2017 Jan;32(1):91-93. doi: 10.1002/mds.26851. Epub 2016 Nov 8. No abstract available.

PMID:
27862260
30.

Is Axonal Degeneration a Key Early Event in Parkinson's Disease?

Kurowska Z, Kordower JH, Stoessl AJ, Burke RE, Brundin P, Yue Z, Brady ST, Milbrandt J, Trapp BD, Sherer TB, Medicetty S.

J Parkinsons Dis. 2016 Oct 19;6(4):703-707. Review.

PMID:
27497486
31.

Ethical and Clinical Considerations at the Intersection of Functional Neuroimaging and Disorders of Consciousness.

Byram AC, Lee G, Owen AM, Ribary U, Stoessl AJ, Townson A, Illes J.

Camb Q Healthc Ethics. 2016 Oct;25(4):613-22. doi: 10.1017/S0963180116000347.

PMID:
27634713
32.

Reply to letter to the editor: Is there anything more to learn from SWEDD?

Wile DJ, Sossi V, Stoessl AJ.

Mov Disord. 2016 Sep;31(9):1426-8. doi: 10.1002/mds.26709. Epub 2016 Aug 13. No abstract available.

PMID:
27519281
33.

Movement disorders.

Stoessl AJ, Mckeown MJ.

Handb Clin Neurol. 2016;136:957-69. doi: 10.1016/B978-0-444-53486-6.00049-1. Review.

PMID:
27430452
34.

Salivary gland biopsy for diagnosis of Parkinson's disease?

Stoessl AJ.

Lancet Neurol. 2016 Jun;15(7):654-656. doi: 10.1016/S1474-4422(16)30031-X. Epub 2016 Apr 18. No abstract available.

PMID:
27102890
35.

The role of biomarkers and imaging in Parkinson's disease.

Algarni MA, Stoessl AJ.

Expert Rev Neurother. 2016;16(2):187-203. doi: 10.1586/14737175.2016.1135056. Epub 2016 Feb 1. Review.

PMID:
26829357
36.

Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?

Stoessl AJ.

Neurology. 2016 Jan 19;86(3):228. doi: 10.1212/WNL.0000000000002297. Epub 2015 Dec 30. No abstract available.

PMID:
26718570
37.

A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.

Wile DJ, Dinelle K, Vafai N, McKenzie J, Tsui JK, Schaffer P, Ding YS, Farrer M, Sossi V, Stoessl AJ.

Mov Disord. 2016 Mar;31(3):405-9. doi: 10.1002/mds.26450. Epub 2015 Dec 21.

38.

Optimizing diagnosis in Parkinson's disease: Radionuclide imaging.

Arena JE, Stoessl AJ.

Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S47-51. doi: 10.1016/j.parkreldis.2015.09.029. Epub 2015 Sep 15. Review.

PMID:
26439947
39.

Canadian perspectives on the clinical actionability of neuroimaging in disorders of consciousness.

Lee G, Byram AC, Owen AM, Ribary U, Stoessl AJ, Townson A, Stables C, Illes J.

Can J Neurol Sci. 2015 Mar;42(2):96-105. doi: 10.1017/cjn.2015.8.

PMID:
25804248
40.

The Saskatchewan Movement Disorders Program: Commitment Pays Off.

Lang AE, Stoessl AJ.

Can J Neurol Sci. 2015 Mar;42(2):70-1. No abstract available.

41.

Imaging in Parkinson's disease: time to look below the neck.

Stoessl AJ.

Brain. 2015 Mar;138(Pt 3):512-4. doi: 10.1093/brain/awu392. No abstract available.

42.

Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.

Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang UJ, Jensen PH, Shi M, Zhang J.

Acta Neuropathol Commun. 2015 Jan 31;3:7. doi: 10.1186/s40478-015-0185-3.

43.

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C.

JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.

44.

DNAJC13 genetic variants in parkinsonism.

Gustavsson EK, Trinh J, Guella I, Vilariño-Güell C, Appel-Cresswell S, Stoessl AJ, Tsui JK, McKeown M, Rajput A, Rajput AH, Aasly JO, Farrer MJ.

Mov Disord. 2015 Feb;30(2):273-8. doi: 10.1002/mds.26064. Epub 2014 Nov 12.

PMID:
25393719
45.

Central pharmacokinetics of levodopa: Lessons from imaging studies.

Stoessl AJ.

Mov Disord. 2015 Jan;30(1):73-9. doi: 10.1002/mds.26046. Epub 2014 Oct 1. Review.

PMID:
25274160
46.

Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism.

Appel-Cresswell S, Rajput AH, Sossi V, Thompson C, Silva V, McKenzie J, Dinelle K, McCormick SE, Vilariño-Güell C, Stoessl AJ, Dickson DW, Robinson CA, Farrer MJ, Rajput A.

Mov Disord. 2014 Nov;29(13):1684-7. doi: 10.1002/mds.26019. Epub 2014 Sep 3.

PMID:
25186792
47.

A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study.

Fujioka S, Boeve BF, Parisi JE, Tacik P, Aoki N, Strongosky AJ, Baker M, Sanchez-Contreras M, Ross OA, Rademakers R, Sossi V, Dickson DW, Stoessl AJ, Wszolek ZK.

Parkinsonism Relat Disord. 2014 Nov;20(11):1129-34. doi: 10.1016/j.parkreldis.2014.07.014. Epub 2014 Aug 19.

48.

DAT-SPECT diagnoses dopamine depletion, but not PD.

Stoessl AJ, Halliday GM.

Mov Disord. 2014 Dec;29(14):1705-6. doi: 10.1002/mds.26000. Epub 2014 Aug 22. No abstract available.

PMID:
25154601
49.

A brain network response to sham surgery.

Cherkasova MV, Stoessl AJ.

J Clin Invest. 2014 Aug;124(8):3285-8. doi: 10.1172/JCI77193. Epub 2014 Jul 18.

50.

Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.

Walker MD, Volta M, Cataldi S, Dinelle K, Beccano-Kelly D, Munsie L, Kornelsen R, Mah C, Chou P, Co K, Khinda J, Mroczek M, Bergeron S, Yu K, Cao LP, Funk N, Ott T, Galter D, Riess O, Biskup S, Milnerwood AJ, Stoessl AJ, Farrer MJ, Sossi V.

J Parkinsons Dis. 2014;4(3):483-98. doi: 10.3233/JPD-140344.

PMID:
25000966

Supplemental Content

Loading ...
Support Center